Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

CXCR4 in Waldenström’s Macroglobulinema: chances and challenges
Lisa Kaiser, Zachary R. Hunter, Steven P. Treon, et al.
Leukemia (2020) Vol. 35, Iss. 2, pp. 333-345
Open Access | Times Cited: 75

Showing 1-25 of 75 citing articles:

The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
Elı́as Campo, Elaine S. Jaffe, James R. Cook, et al.
Blood (2022) Vol. 140, Iss. 11, pp. 1229-1253
Open Access | Times Cited: 975
Super-enhancer hypermutation alters oncogene expression in B cell lymphoma
Élodie Bal, Rahul Kumar, Mohammad Hadigol, et al.
Nature (2022) Vol. 607, Iss. 7920, pp. 808-815
Open Access | Times Cited: 99
Waldenström macroglobulinemia: 2023 update on diagnosis, risk stratification, and management
Morie A. Gertz
American Journal of Hematology (2023) Vol. 98, Iss. 2, pp. 348-358
Open Access | Times Cited: 51
A comparison of the International Consensus and 5th World Health Organization classifications of mature B-cell lymphomas
Brunangelo Falini, Giovanni Martino, Stefano Lazzi
Leukemia (2022) Vol. 37, Iss. 1, pp. 18-34
Open Access | Times Cited: 45
New genetic and epigenetic insights into the chemokine system: the latest discoveries aiding progression toward precision medicine
Hanli Xu, Shuye Lin, Ziyun Zhou, et al.
Cellular and Molecular Immunology (2023) Vol. 20, Iss. 7, pp. 739-776
Open Access | Times Cited: 32
Targeting BTK in B Cell Malignancies: From Mode of Action to Resistance Mechanisms
Samir Mouhssine, Nawar Maher, Bassam Francis Matti, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 6, pp. 3234-3234
Open Access | Times Cited: 13
Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenström macroglobulinemia
Constantine S. Tam, Stephen Opat, Shirley D’Sa, et al.
Blood Advances (2024) Vol. 8, Iss. 7, pp. 1639-1650
Open Access | Times Cited: 12
CXCR4: from B-cell development to B cell–mediated diseases
Stéphane Giorgiutti, Julien Rottura, Anne‐Sophie Korganow, et al.
Life Science Alliance (2024) Vol. 7, Iss. 6, pp. e202302465-e202302465
Open Access | Times Cited: 9
Simplified Risk Stratification Model for Patients With Waldenström Macroglobulinemia
Saurabh Zanwar, Jennifer Le‐Rademacher, Éric Durot, et al.
Journal of Clinical Oncology (2024) Vol. 42, Iss. 21, pp. 2527-2536
Open Access | Times Cited: 9
Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenström macroglobulinemia
Steven P. Treon, Kirsten Meid, Zachary R. Hunter, et al.
Blood (2021) Vol. 138, Iss. 17, pp. 1535-1539
Open Access | Times Cited: 46
Evaluation of orelabrutinib monotherapy in patients with relapsed or refractory Waldenström's macroglobulinemia in a single-arm, multicenter, open-label, phase 2 study
Xinxin Cao, Jie Jin, Chengcheng Fu, et al.
EClinicalMedicine (2022) Vol. 52, pp. 101682-101682
Open Access | Times Cited: 32
Managing Waldenström’s macroglobulinemia with BTK inhibitors
Christian Buske, Wojciech Jurczak, Joe-Élie Salem, et al.
Leukemia (2022) Vol. 37, Iss. 1, pp. 35-46
Open Access | Times Cited: 27
How I use genomics and BTK inhibitors in the treatment of Waldenström macroglobulinemia
Steven P. Treon, Shayna Sarosiek, Jorge J. Castillo
Blood (2024) Vol. 143, Iss. 17, pp. 1702-1712
Open Access | Times Cited: 5
Prognostic impact of MYD88 and CXCR4 mutations assessed by droplet digital polymerase chain reaction in IgM monoclonal gammopathy of undetermined significance and smouldering Waldenström macroglobulinaemia
David F. Moreno, Mònica López‐Guerra, Sara Paz, et al.
British Journal of Haematology (2022) Vol. 200, Iss. 2, pp. 187-196
Open Access | Times Cited: 21
Report of Consensus Panel 3 from the 11th International workshop on Waldenström's Macroglobulinemia: Recommendations for molecular diagnosis in Waldenström's Macroglobulinemia
Ramón García‐Sánz, Marzia Varettoni, Cristina Jiménez, et al.
Seminars in Hematology (2023) Vol. 60, Iss. 2, pp. 90-96
Open Access | Times Cited: 12
Single-cell RNA sequencing defines distinct disease subtypes and reveals hypo-responsiveness to interferon in asymptomatic Waldenstrom’s Macroglobulinemia
Romanos Sklavenitis‐Pistofidis, Yoshinobu Konishi, Daniel Heilpern-Mallory, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access
CXCR4 Inhibition Enhances the Efficacy of CD19 Monoclonal Antibody-Mediated Extermination of B-Cell Lymphoma
Nupur Khunti, Manish Kumar, Moumita Datta, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 5, pp. 2024-2024
Open Access
Molecular Mechanisms in the Transformation from Indolent to Aggressive B Cell Malignancies
Nawar Maher, Samir Mouhssine, Bassam Francis Matti, et al.
Cancers (2025) Vol. 17, Iss. 5, pp. 907-907
Open Access
Amyloidosis-Related Cardiomyopathy Revealing Waldenstrom Macroglobulinemia: A Case Report
M. Tariq, Klara Lunte, Carole Fleury, et al.
Cureus (2025)
Open Access
New developments in the diagnosis and characterization of Waldenström’s macroglobulinemia
Ramón García‐Sánz, Zachary R. Hunter, Stéphanie Poulain, et al.
Expert Review of Hematology (2023) Vol. 16, Iss. 11, pp. 835-847
Open Access | Times Cited: 10
Report of Consensus Panel 3 from the 12th International Workshop on Waldenström's Macroglobulinemia on the Management of Patients with High-Risk Disease.
Prashant Kapoor, Meletios Α. Dimopoulos, Stephen M. Ansell, et al.
Seminars in Hematology (2025)
Closed Access
Targeting BCL2 in Waldenström macroglobulinemia: from biology to treatment management
Eleni Kalafati, Efstathios Kastritis, Tina Bagratuni
Frontiers in Oncology (2025) Vol. 15
Open Access
How to manage waldenström’s macroglobulinemia in 2024
Alexander Grunenberg, Christian Buske
Cancer Treatment Reviews (2024) Vol. 125, pp. 102715-102715
Open Access | Times Cited: 3
New developments in non-Hodgkin lymphoid malignancies
Karthik A. Ganapathi, Laura Brown, Sonam Prakash, et al.
Pathology (2021) Vol. 53, Iss. 3, pp. 349-366
Closed Access | Times Cited: 20
A genetic profiling guideline to support diagnosis and clinical management of lymphomas
Margarita Sánchez‐Beato, Míriam Méndez, M. Guirado, et al.
Clinical & Translational Oncology (2023) Vol. 26, Iss. 5, pp. 1043-1062
Open Access | Times Cited: 7
Page 1 - Next Page

Scroll to top